ClinicalTrials.gg
CompletedNCT06389955Updated Sep 19, 2024

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

A Phase 1 interventional study of TP 3654 in Healthy, sponsored by Sumitomo Pharma America, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.
  • Registered 11 months after the study started (first participant enrolled May 2023, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study comprised of 2 parts, Part A and Part B. Part B will only be conducted if the relative bioavailability of the tablet formulation was at least 70% of the capsule formulation.

Read the detailed description

Part A is a randomized, single-dose, 4-period, 4-way cross-over study to evaluate the effect of food on the TP 3654 capsule and assess the relative bioavailability of the TP-3654 capsule versus tablet formulations. Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit (CRU) on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants will be randomly assigned to a treatment sequence, and they will receive TP-3654 per their assigned sequence.

Part B is a randomized, single-dose, 3-period, 3-way cross-over study to evaluate the effect of food on the PK of the TP-3654 tablet formulation. Following a screening period of up to 28 days, eligible participants will be admitted to the CRU on Day -1. As with Part A, participants will fast overnight from Day -1 to Day 1. On Day 1, they will be randomly assigned to a treatment sequence, and they will receive TP-3654 per their assigned sequence.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.

First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided written .
  2. Participant is ≥ 18 to ≤ 65 years of age.
  3. Participant is willing and able to consume the prescribed standard meals.
  4. Participant agrees to use an acceptable method of as described in Section 8.5.4 for the duration of the study and agrees to continue use for 3 months after the final dose (male participants) or for 6 months after the final dose (female participants).
  5. Male participant agrees not to donate sperm during the study and for 3 months after the last dose of study drug. Female participant agrees not to donate eggs for the duration of the study and for 6 months after the last dose of study drug.
  6. Participant has a ≥ 18.5 and ≤ 32 kg/m2 at screening.
  7. Participant is generally healthy, as determined by the Investigator based on medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead (ECG) at screening. In particular:

    1. Clinical laboratory results must be within normal range
    2. Body temperature is \< 38°C (100.3°F).
    3. Blood pressure and heart rate are within normal limits (systolic blood pressure is ≥ 90 to ≤ 150 mmHg; supine diastolic blood pressure is ≥ 50 to ≤ 90 mmHg; heart rate is ≥ 40 to ≤ 90 bpm) at screening.
    4. Average triplicate interval (QTcF) ≤ 430 msec (for male participants) or ≤ 450 msec (for female participants).
  8. Participant agrees to avoid the use of concomitant medications (except hormonal contraception or medication provided by the site staff under the direction of the Investigator) from screening through the final follow-up visit.
  9. Participant agrees to abstain from alcohol, recreational drugs (including marijuana), and nicotine from screening through the final follow-up visit.
  10. Participant is willing and able to remain confined in the Clinical Research Unit for the duration of the inpatient period (13 days for Part A or 10 days for Part B)

Exclusion criteria

Exclusion Criteria:

  1. Participant is pregnant (as evidenced by a positive pregnancy test) or nursing.
  2. Participant reports a history (within 3 years prior to screening) of any neurological, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine, hematological, dermatological, psychological, or other disorders as determined by the Investigator.
  3. Participant reports use of hepatic microsomal enzyme interacting drugs (such as voriconazole, fluconazole, cimetidine) within 30 days prior to admission.
  4. Participant reports being exposed to an product (drug, biologic, or device) within 30 days preceding the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
  5. Participant reports having a surgical procedure that may affect drug absorption, distribution, metabolism, and/or excretion (eg, bariatric procedure, cholecystectomy). Appendectomy is acceptable.
  6. Participant reports donating blood within 8 weeks before the first dose administration.
  7. Participant reports a history of alcohol or drug use disorder within 2 years before screening.
  8. Participant has a positive drug screening test reflecting use of recreational drugs.
  9. Participant reports being a current smoker or use of nicotine products (eg, nicotine gum or patch, vaporized nicotine, chewing tobacco)
  10. Participant has poor venous access or has a history of difficulty providing blood samples.
  11. Participant reports any condition or has any finding that would, in the Investigator's opinion, put the participant or study conduct at risk if the participant were to be enrolled in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Part A - Sequence 1

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 1 will take TP 3654 with or without food as follows: Day 1 - 480mg (4 x 120mg capsules) once daily with low fat meal, Day 4 - 480mg (4 x 120mg capsules) once daily fasted, Day 7 - 480mg (4 x 120mg capsules) once daily with high fat meal, and Day 10 - 480mg (2 x 240mg tablets) once daily fasted.

    Drug: TP 3654

  • Experimental
    Part A - Sequence 2

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 2 will take TP 3654 with or without food as follows: Day 1 - 480mg (4 x 120mg capsules) once daily fasted, Day 4 - 480mg (2 x 240mg tablets) once daily fasted, Day 7 - 480mg (4 x 120mg capsules) once daily with low fat meal, and Day 10 - 480mg (4 x 120mg capsules) once daily with high fat meal.

    Drug: TP 3654

  • Experimental
    Part A - Sequence 3

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 3 will take TP 3654 with or without food as follows: Day 1 - 480mg (2 x 240mg tablets) once daily fasted, Day 4 - 480mg (4 x 120mg capsules) once daily with high fat meal, Day 7 - 480mg (4 x 120mg capsules) once daily fasted, and Day 10 - 480mg (4 x 120mg capsules) once daily with low fat meal.

    Drug: TP 3654

  • Experimental
    Part A - Sequence 4

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 4 will take TP 3654 with or without food as follows: Day 1 - 480mg (4 x 120mg capsules) once daily with high fat meal, Day 4 - 480mg (4 x 120mg capsules) once daily with low fat meal, Day 7 - 480mg (2 x 240mg tablets) once daily fasted, and Day 10 - 480mg (4 x 120mg capsules) once daily fasted.

    Drug: TP 3654

  • Experimental
    Part B - Sequence 1

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 1 will take TP 3654 tablets with or without food as follows: Day 1 - 480mg once daily with low fat meal, Day 4 - 480mg once daily fasted, and Day 7 - 480mg once daily with high fat meal.

    Drug: TP 3654

  • Experimental
    Part B - Sequence 2

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 2 will take TP 3654 tablets with or without food as follows: Day 1 - 480mg once daily fasted, Day 4 - 480mg once daily with high fat meal, and Day 7 - 480mg once daily with low fat meal.

    Drug: TP 3654

  • Experimental
    Part B - Sequence 3

    Following a screening period of up to 28 days, eligible participants will be admitted to the clinical research unit on Day -1. Participants will fast overnight from Day -1 to Day 1. On Day 1, participants randomly assigned to Sequence 3 will take TP 3654 tablets with or without food as follows: Day 1 - 480mg once daily with high fat meal, Day 4 - 480mg once daily with low fat meal, and Day 7 - 480mg once daily fasted.

    Drug: TP 3654

Interventions

  • TP 3654 is an investigational orally delivered drug

06

What researchers measure

Primary outcomes

  1. Part A - The maximum concentration (Cmax) of TP-3654 in a capsule formulation

    Time frame: 2 weeks

  2. Part A - The area under the curve (AUC) of TP-3654 in a capsule formulation

    Time frame: 2 weeks

  3. Part A - Ratio of Peak Plasma Concentration (Cmax) of TP-3654 tablet versus TP-3654 capsule under fasted conditions

    Time frame: 2 weeks

  4. Part B - The maximum concentration (Cmax) of TP-3654 in a tablet formulation

    Time frame: 2 weeks

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAE)

    TEAEs will be monitored from first dose to 30 days after the last dose

    Time frame: 6 weeks

07

Study locations

1 site
  • Frontage Investigative Site
    Secaucus, New Jersey 07094, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Aug 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 29, 2024
StartActual
May 22, 2023
Primary completionActual
Aug 1, 2023
CompletionActual
Aug 24, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06389955
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
May 22, 2023
Primary completion
Aug 1, 2023
Completion
Aug 24, 2023
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TP 3654

Start the discussion